Conference abstractPublished 5 Jul 2011
New and future management of retinal vein occlusive disease
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Retinal vein occlusions (RVOs) are the second most common form of retinal vascular disease and affects more than 100,000patients per year. The predominant causes for vision loss from RVOs include macular edema and macular ischemia. Data from historic studies recommended focal macular laser only for branch vein occlusion patients with macular edema and >20/40 vision within 3-18 months of onset and without significant retinal hemorrhages. No treatment for macular edema was recommended for central vein occlusion patients. For years, the standard of care has been extrapolated from these historic studies. However, exciting new data from five multicenter randomized controlled studies using Ranibizumab (BRAVO and CRUISE Studies),Posurdex (Ozurdex for RVO studies), and Triamcinolone Acetonide(SCORE Study) for the treatment of macular edema in vein occlusions has yielded impressive results, reshaping the management of retinal vein occlusions. The discussion will focus on the natural history of retinal vein occlusions, salient poi nts of these new trials, and an informative review of the ongoing or planned randomized clinical trials.
Subjects
Ophthalmology & OptometryAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical and Experimental Ophthalmology
- SubjectOphthalmology & Optometry
- BylineArticles whose byline prints “Rishi P. Singh”
